BioSpace News Archive

Psomagen, Inc., a North American sequencing-based contract laboratory service and data analysis provider with both CLIA-certified and CAP-accredited facilities, has partnered with Olink Proteomics, which offers an innovative DNA-coupled immunoassay that identifies and quantifies protein biomarkers in clinical samples.

Biomind Labs to Present at H.C. Wainwright 2nd Annual Psychedelics Conference

Cybin Inc. will present virtually at the Jefferies London Healthcare Conference being held virtually November 18-19, 2021.

The New England Journal of Medicine has published findings from a pilot study that has shown how whole genome sequencing (WGS) uncovered new diagnoses for patients across the broadest range of rare diseases.

Emmaus Life Sciences, Inc. (OTCQX: EMMA) today announced a partnership with UpScript IP Holdings, LLC. (UpScript), to offer telehealth solutions to sickle cell disease patients, expanding access to Endari®, Emmaus’ prescription L-glutamine oral powder for the treatment of sickle cell disease.

Milestone Scientific Inc. today announced it will host a conference call at 11:00 A.M. Eastern Time on Monday, November 15, 2021 to discuss the Company’s financial results for the third quarter ended September 30, 2021, as well as the Company’s corporate progress and other developments.

Aerami Therapeutics, Inc., a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the appointment of Darlene Deptula–Hicks, Chief Financial Officer of F-star Therapeutics, Inc., to its board of directors and chair of the audit committee.

Quoin Pharmaceuticals Ltd. and Genpharm Services today announced that they have entered into an exclusive License and Distribution Agreement for QRX003, Quoin’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease.

Rockwell Medical, Inc. today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC)

Echosens, a high-technology company offering the FibroScan® family of products, is pleased to announce its strong presence at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, a digital conference, Nov. 12-15, 2021, with FibroScan-based solutions - referenced in 19 oral presentations and 180 poster presentations.